Sign in

CIK 0001636282

  • Large accelerated filer

Spyre Therapeutics, Inc.

Sign in to watch
Ticker
SYRE
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
464312787
Phone
+1 617-651-5940
Business address
221 CRESCENT STREET, BUILDING 23, SUITE 105, WALTHAM, MA, 02453
Former names
Aeglea BioTherapeutics, Inc.
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$12,349,597
in 6 filings, $12.3M under 10b5-1 plans

Net −$12,349,597. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Reading 21 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2023-02-23 Hanley Jr. Michael Conick Chief Business Officer Grant or award · Employee Stock Option (right to buy) +500,000 500,000
2022-08-23 Hanley Jr. Michael Conick Chief Business Officer Grant or award · Employee Stock Option (right to buy) +130,000 130,000
2022-06-08 Hanley Jr. Michael Conick Chief Commercial Officer Purchase +28,200 $0.71 $20K 36,200
2022-02-17 Hanley Jr. Michael Conick Chief Commercial Officer Grant or award · Employee Stock Option (right to buy) +160,000 160,000
2021-02-17 Hanley Jr. Michael Conick Chief Commercial Officer Grant or award · Employee Stock Option (right to buy) +135,000 135,000
2020-02-14 Hanley Jr. Michael Conick Chief Commercial Officer Grant or award · Employee Stock Option (right to buy) +25,000 25,000
2019-10-21 Hanley Jr. Michael Conick Chief Commercial Officer Grant or award · Employee Stock Option (right to buy) +130,000 130,000

Page 1 of 1 · 7 trades